Salarius Pharmaceuticals Inc
Salarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufac… Read more
Salarius Pharmaceuticals Inc (SLRX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.388x
Based on the latest financial reports, Salarius Pharmaceuticals Inc (SLRX) has a cash flow conversion efficiency ratio of -0.388x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.65 Million) by net assets ($4.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Salarius Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Salarius Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Salarius Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Salarius Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Scandinavian Real Heart AB (Publ)
F:7820
|
-0.026x |
|
TVA Group Inc
PINK:TVAGF
|
0.152x |
|
Vaishali Pharma Limited
NSE:VAISHALI
|
0.030x |
|
Plaza Centers NV
WAR:PLZ
|
0.001x |
|
Genesis Fertility Center Public Company Limited
BK:GFC
|
0.022x |
|
Nam Song Hau Trading Investing Petroleum JSC
VN:PSH
|
N/A |
|
Interra Copper Corp
OTCQB:IMIMF
|
-2.146x |
|
MedNation AG
XETRA:EIF
|
N/A |
Annual Cash Flow Conversion Efficiency for Salarius Pharmaceuticals Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Salarius Pharmaceuticals Inc from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.51 Million | $-4.53 Million | -2.994x | -23.21% |
| 2023-12-31 | $5.29 Million | $-12.85 Million | -2.430x | -43.39% |
| 2022-12-31 | $10.38 Million | $-17.60 Million | -1.694x | -543.23% |
| 2021-12-31 | $38.72 Million | $-10.20 Million | -0.263x | +43.39% |
| 2020-12-31 | $22.16 Million | $-10.31 Million | -0.465x | +57.48% |
| 2019-12-31 | $10.58 Million | $-11.58 Million | -1.094x | +56.95% |
| 2018-12-31 | $9.28 Million | $-23.60 Million | -2.542x | -166.91% |
| 2017-12-31 | $29.11 Million | $-27.72 Million | -0.952x | -76.27% |
| 2016-12-31 | $59.32 Million | $-32.05 Million | -0.540x | -140.12% |
| 2015-12-31 | $92.19 Million | $-20.75 Million | -0.225x | -- |